NCT03985046View on ClinicalTrials.gov

Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 10, 2019

Primary Completion Date

May 31, 2021

Study Completion Date

December 31, 2022

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Sintilimab plus Chemotherapy

Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=5. Once every 3 weeks.

Trial Locations (1)

200032

Fudan Universtiy Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT03985046 - Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC | Biotech Hunter | Biotech Hunter